Sanbio brings its Japanese retail fans down to earth
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
Japanese biopharma rules mid-cap returns
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.